NCT05216510View on ClinicalTrials.gov

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

September 17, 2022

Study Completion Date

September 17, 2022

Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
BIOLOGICAL

TNX-2110

TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.

BIOLOGICAL

TNX-2120

TNX-2120 represents the spike protein and is administered intradermally.

BIOLOGICAL

TNX-2130

TNX-2130 represents non-spike proteins and is administered intradermally.

BIOLOGICAL

CANDIN

Candida albicans antigens to be administered intradermally as a positive control.

BIOLOGICAL

Diluent

Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.

Trial Locations (1)

08009

Clinical Site, Berlin

Sponsors
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT05216510 - Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens | Biotech Hunter | Biotech Hunter